Health Care·Biotechnology·$8.0B
Krystal Biotech Inc is a biotechnology company focused on developing gene therapies for patients with rare diseases. With a market cap of $8 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to reshape treatment options for various conditions.
EPS (Earnings Per Share)
EPS is a key indicator of the company's profitability and performance, which investors closely monitor.
Revenue Growth
Although revenue figures are not available, any insights into growth will indicate the company's market traction and product adoption.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
2Q
EPS Beat Rate
63%
Avg EPS Surprise
+9.99%
Avg Stock Reaction
-2.87%
In the last quarter, Krystal Biotech reported an EPS of $1.70, exceeding estimates by nearly 5%. The stock responded positively, gaining over 4% the following day.
Management Promises & Guidance
Overall, expectations for Krystal Biotech's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors will be keen to see if the company can maintain its recent positive momentum.
Bull Case
If Krystal Biotech reports strong earnings and positive updates on its gene therapy programs, it could validate investor confidence and drive the stock higher.
Bear Case
Conversely, if the company fails to meet expectations or provides disappointing updates on its clinical trials, it may lead to a significant sell-off.
EPS (Earnings Per Share)
N/AEPS is a key indicator of the company's profitability and performance, which investors closely monitor.
Revenue Growth
N/AAlthough revenue figures are not available, any insights into growth will indicate the company's market traction and product adoption.
The print will turn on these two things.
Q1
What is the current status of ongoing clinical trials?
Updates on clinical trials will provide insight into the company's progress and potential revenue streams, which are crucial for investor confidence.
Q2
Can the company provide guidance on future EPS or revenue expectations?
Any forward-looking guidance will help investors gauge the company's growth trajectory and financial health.
Why consensus could be wrong
The Street may underestimate the potential impact of Krystal Biotech's innovative gene therapies, which could significantly outperform expectations if trial results are favorable.
Supporting Evidence
The company has a strong track record of beating EPS estimates, with a 63% beat rate over the last eight quarters.
Recent positive market reactions to similar biotech companies suggest a favorable environment for Krystal Biotech.
The lack of analyst estimates may lead to lower expectations, providing room for positive surprises.
Key Risk
If the clinical trial results exceed expectations, it could lead to a substantial reevaluation of the company's growth potential.
Pre-commit to what would confirm each case.
The market is weighing the potential for growth against the risks associated with clinical trials and regulatory approvals.
Bull Confirmed If
A positive update on clinical trial results or new partnerships that could enhance revenue potential.
Bear Confirmed If
Any negative news regarding trial outcomes or lack of guidance could lead to a significant decline in stock price.
Implied Move
±N/A
There is no options market data available to gauge investor sentiment ahead of the earnings report.
Cross-company pattern from 30 similar setups.
Prior-quarter beat setup in Health Care
n=30Fade rate: 7 of 20 (35%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.9%, with a raw directional average of +2.3% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Krystal Biotech beats expectations, history suggests a potential stock increase of around 1.55%, confirming the company's growth narrative.
In-Line / Cautious
An in-line report may lead to a muted reaction, with the stock likely to remain stable as investors await further clarity from management.
Miss
If the company misses expectations, history suggests a decline of around 10.23%, which could trigger a sell-off as investors reassess their outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SOLENO THERAPEUTICS
Mar 18, 2019